Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
27
10
2022
accepted:
05
02
2023
medline:
5
6
2023
pubmed:
4
3
2023
entrez:
3
3
2023
Statut:
ppublish
Résumé
Thyroid dysfunction is a common adverse event after immune checkpoint inhibitor (ICI) therapy. The clinical manifestations of thyroid immune-related adverse events (irAEs) are variable and the underlying mechanisms remain unclear. To identify the clinical and biochemical characteristics of Chinese patients with ICI-related thyroid dysfunction. We retrospectively reviewed patients with carcinoma who received ICI therapy and underwent evaluation of thyroid function during hospitalization at Peking Union Medical College Hospital between January 1, 2017 and December 31, 2020. Clinical and biochemical features were analyzed in patients who developed ICI-related thyroid dysfunction. Survival analyses were performed to determine the effect of thyroid autoantibodies on thyroid abnormalities and the impact of thyroid irAEs on clinical outcomes. The cohort included 270 patients with a median follow-up of 17.7 months; 120 (44%) of these patients developed thyroid dysfunction on immunotherapy. The most common thyroid irAE was overt hypothyroidism (with/without transient thyrotoxicosis), which occurred in 38% of patients (n = 45), followed by subclinical thyrotoxicosis (n = 42), subclinical hypothyroidism (n = 27), and isolated overt thyrotoxicosis (n = 6). The median time to first clinical presentation was 49 days (interquartile range 23, 93) for thyrotoxicosis and 98 days (interquartile range 51, 172) for hypothyroidism. In patients treated with PD-1 inhibitors, hypothyroidism was strongly associated with younger age (odds ratio [OR] 0.44, 95% confidence interval [CI] 0.29-0.67; P < 0.001), previous thyroid disease (OR 4.30, 95% CI 1.54-11.99; P = 0.005), and a higher baseline thyroid-stimulating hormone level (OR 2.76, 95% CI 1.80-4.23; P < 0.001). Thyrotoxicosis was only associated with the baseline thyroid-stimulating hormone (TSH) level (OR 0.59, 95% CI 0.37-0.94; P = 0.025). Thyroid dysfunction after initiation of ICI therapy was associated with better progression-free survival (hazard ratio [HR] 0.61, 95% CI 0.44-0.86; P = 0.005) and overall survival (hazard ratio 0.67, 95% CI 0.45-0.99; P = 0.046). Anti-thyroglobulin antibody positivity increased the risk of thyroid irAEs. The occurrence of thyroid irAEs with diverse phenotypes is common. Distinct clinical and biochemical characteristics suggest heterogeneity among different subgroups of thyroid dysfunction, which requires further research to explore the under mechanism.
Sections du résumé
BACKGROUND
Thyroid dysfunction is a common adverse event after immune checkpoint inhibitor (ICI) therapy. The clinical manifestations of thyroid immune-related adverse events (irAEs) are variable and the underlying mechanisms remain unclear.
PURPOSE
To identify the clinical and biochemical characteristics of Chinese patients with ICI-related thyroid dysfunction.
METHODS
We retrospectively reviewed patients with carcinoma who received ICI therapy and underwent evaluation of thyroid function during hospitalization at Peking Union Medical College Hospital between January 1, 2017 and December 31, 2020. Clinical and biochemical features were analyzed in patients who developed ICI-related thyroid dysfunction. Survival analyses were performed to determine the effect of thyroid autoantibodies on thyroid abnormalities and the impact of thyroid irAEs on clinical outcomes.
RESULTS
The cohort included 270 patients with a median follow-up of 17.7 months; 120 (44%) of these patients developed thyroid dysfunction on immunotherapy. The most common thyroid irAE was overt hypothyroidism (with/without transient thyrotoxicosis), which occurred in 38% of patients (n = 45), followed by subclinical thyrotoxicosis (n = 42), subclinical hypothyroidism (n = 27), and isolated overt thyrotoxicosis (n = 6). The median time to first clinical presentation was 49 days (interquartile range 23, 93) for thyrotoxicosis and 98 days (interquartile range 51, 172) for hypothyroidism. In patients treated with PD-1 inhibitors, hypothyroidism was strongly associated with younger age (odds ratio [OR] 0.44, 95% confidence interval [CI] 0.29-0.67; P < 0.001), previous thyroid disease (OR 4.30, 95% CI 1.54-11.99; P = 0.005), and a higher baseline thyroid-stimulating hormone level (OR 2.76, 95% CI 1.80-4.23; P < 0.001). Thyrotoxicosis was only associated with the baseline thyroid-stimulating hormone (TSH) level (OR 0.59, 95% CI 0.37-0.94; P = 0.025). Thyroid dysfunction after initiation of ICI therapy was associated with better progression-free survival (hazard ratio [HR] 0.61, 95% CI 0.44-0.86; P = 0.005) and overall survival (hazard ratio 0.67, 95% CI 0.45-0.99; P = 0.046). Anti-thyroglobulin antibody positivity increased the risk of thyroid irAEs.
CONCLUSIONS
The occurrence of thyroid irAEs with diverse phenotypes is common. Distinct clinical and biochemical characteristics suggest heterogeneity among different subgroups of thyroid dysfunction, which requires further research to explore the under mechanism.
Identifiants
pubmed: 36867366
doi: 10.1007/s12020-023-03323-9
pii: 10.1007/s12020-023-03323-9
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Thyrotropin
9002-71-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-133Subventions
Organisme : Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science
ID : 2021-1-I2M-022
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
D.M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 37, 252–264 (2012)
doi: 10.1038/nrc3239
P. Sharma, J.P. Allison, The future of immune checkpoint therapy. Science 348, 56–61 (2015)
doi: 10.1126/science.aaa8172
pubmed: 25838373
R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro, F.S. Hodi, L. Min, I.E. Krop, S.M. Tolaney, Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 4, 173–182 (2018)
doi: 10.1001/jamaoncol.2017.3064
pubmed: 28973656
Y. Shi, J. Fang, C. Zhou, A. Liu, Y. Wang, Q. Meng, C. Ding, B. Ai, Y. Gu, Y. Yao, H. Sun, H. Guo, C. Zhang, X. Song, J. Li, B. Xu, Z. Han, M. Song, T. Tang, P. Chen, H. Lu, Y. Shui, G. Lou, D. Zhang, J. Liu, X. Liu, X. Liu, X. Gao, Q. Zhou, M. Chen, J. Zhao, W. Zhong, Y. Xu, M. Wang, Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. Thorac. Cancer 13, 412–422 (2022)
doi: 10.1111/1759-7714.14274
pubmed: 34935288
C.A. Muir, A.M. Menzies, R. Clifton-Bligh, V.H.M. Tsang, Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer. Thyroid 30, 1458–1469 (2020)
doi: 10.1089/thy.2020.0032
pubmed: 32264785
J.C. Osorio, A. Ni, J.E. Chaft, R. Pollina, M.K. Kasler, D. Stephens, C. Rodriguez, L. Cambridge, H. Rizvi, J.D. Wolchok, T. Merghoub, C.M. Rudin, S. Fish, M.D. Hellmann, Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann. Oncol. 28, 583–589 (2017)
doi: 10.1093/annonc/mdw640
pubmed: 27998967
T. Kobayashi, S. Iwama, Y. Yasuda, N. Okada, T. Tsunekawa, T. Onoue, H. Takagi, D. Hagiwara, Y. Ito, Y. Morishita, M. Goto, H. Suga, R. Banno, K. Yokota, T. Hase, M. Morise, N. Hashimoto, M. Ando, H. Kiyoi, M. Gotoh, Y. Ando, M. Akiyama, Y. Hasegawa, H. Arima, Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J. Endocr. Soc. 2, 241–251 (2018)
doi: 10.1210/js.2017-00432
pubmed: 29600292
pmcid: 5836529
S. Kimbara, Y. Fujiwara, S. Iwama, K. Ohashi, A. Kuchiba, H. Arima, N. Yamazaki, S. Kitano, N. Yamamoto, Y. Ohe, Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci. 109, 3583–3590 (2018)
doi: 10.1111/cas.13800
pubmed: 30230649
pmcid: 6215874
P.C. Iyer, M.E. Cabanillas, S.G. Waguespack, M.I. Hu, S. Thosani, V.R. Lavis, N.L. Busaidy, S.K. Subudhi, A. Diab, R. Dadu, Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid 28, 1243–1251 (2018)
doi: 10.1089/thy.2018.0116
pubmed: 30132401
pmcid: 6157359
E.S. Scott, G.V. Long, A. Guminski, R.J. Clifton-Bligh, A.M. Menzies, V.H. Tsang, The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur. J. Endocrinol. 178, 173–180 (2018)
doi: 10.1530/EJE-17-0810
pubmed: 29187509
B.A. Helmink, P.O. Gaudreau, J.A. Wargo, Immune checkpoint blockade across the cancer care continuum. Immunity 48, 1077–1080 (2018)
doi: 10.1016/j.immuni.2018.06.003
pubmed: 29924973
H.I. Kim, M. Kim, S-H. Lee, S.Y. Park, Y.N. Kim, H. Kim, M.J. Jeon, T.Y. Kim, S.W. Kim, W.B. Kim, S.-W. Kim, D.H. Lee, K. Park, M.-J.Ahn, J. H. Chung, Y. K. Shong, W. G. Kim, T.H. Kim, Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology. (2017). https://doi.org/10.1080/2162402X.2017.1375642
K. Haratani, H. Hayashi, Y. Chiba, K. Kudo, K. Yonesaka, R. Kato, H. Kaneda, Y. Hasegawa, K. Tanaka, M. Takeda, K. Nakagawa, Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 4, 374–378 (2018)
doi: 10.1001/jamaoncol.2017.2925
pubmed: 28975219
A. Kotwal, L. Kottschade, M. Ryder, PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 30, 177–184 (2020)
doi: 10.1089/thy.2019.0250
pubmed: 31813343
pmcid: 7047075
C.A. Muir, R.J. Clifton-Bligh, G.V. Long, R.A. Scolyer, S.N. Lo, M.S. Carlino, V.H.M. Tsang, A.M. Menzies, Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J. Clin. Endocrinol. Metab. 106, e3704–e3713 (2021)
doi: 10.1210/clinem/dgab263
pubmed: 33878162
I. Yamauchi, A. Yasoda, S. Matsumoto, Y. Sakamori, Y.H. Kim, M. Nomura, A. Otsuka, T. Yamasaki, R. Saito, M. Kitamura, T. Kitawaki, M. Hishizawa, N. Kawaguchi-Sakita, T. Fujii, D. Taura, M. Sone, N. Inagaki, Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One (2019). https://doi.org/10.1371/journal.pone.0216954
C. Kurimoto, H. Inaba, H. Ariyasu, H. Iwakura, Y. Ueda, S. Uraki, K. Takeshima, Y. Furukawa, S. Morita, Y. Yamamoto, S. Yamashita, M. Katsuda, A. Hayata, H. Akamatsu, M. Jinnin, I. Hara, H. Yamaue, T. Akamizu, Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 111, 1468–1477 (2020)
doi: 10.1111/cas.14363
pubmed: 32086984
pmcid: 7226278
H.S. Baek, C. Jeong, K. Shin, J. Lee, H. Suh, D.J. Lim, M.I. Kang, J. Ha. Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. BMC Endocr Disord. (2022). https://doi.org/10.1186/s12902-022-01004-8
S. Iwama, T. Kobayashi, Y. Yasuda, T. Okuji, M. Ito, M. Ando, X. Zhou, A. Yamagami, T. Onoue, Y. Kawaguchi, T. Miyata, M. Sugiyama, H. Takagi, D. Hagiwara, H. Suga, R. Banno, T. Hase, M. Morise, K. Wakahara, K. Yokota, M. Kato, N. Nishio, C. Tanaka, K. Miyata, A. Ogura, T. Ito, T. Sawada, T. Shimokata, K. Niimi, F. Ohka, M. Ishigami, M. Gotoh, N. Hashimoto, R. Saito, H. Kiyoi, H. Kajiyama, Y. Ando, H. Hibi, M. Sone, M. Akiyama, Y. Kodera, H. Arima, Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. J. Clin. Endocrinol. Metab. 107, e1620–e1630 (2022)
doi: 10.1210/clinem/dgab829
pubmed: 34791304
N. Zhou, M.A. Velez, B. Bachrach, J. Gukasyan, C.M. Fares, A.L. Cummings, J.P. Lind-Lebuffe, W.O. Akingbemi, D.Y. Li, P.M. Brodrick, N.M. Yessuf, S. Rettinger, T. Grogan, P. Rochigneux, J.W. Goldman, E.B. Garon, A. Lisberg, Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. Lung Cancer 161, 34–41 (2021)
doi: 10.1016/j.lungcan.2021.08.009
pubmed: 34507111
H. Lee, F.S. Hodi, A. Giobbie-Hurder, P.A. Ott, E.I. Buchbinder, R. Haq, S. Tolaney, R. Barroso-Sousa, K. Zhang, H. Donahue, M. Davis, M.E. Gargano, K.M. Kelley, R.S. Carroll, U.B. Kaiser, L. Min, Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol. Res 5, 1133–1140 (2017)
doi: 10.1158/2326-6066.CIR-17-0208
pubmed: 29079654
pmcid: 5748517
R.M. Ruggeri, A. Campenni, G. Giuffrida, P. Trimboli, L. Giovanella, F. Trimarchi, S. Cannavo, Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J. Endocrinol. Investig. 42, 745–756 (2019)
doi: 10.1007/s40618-018-0984-z
N. Ghosh, K.K. Chan, B. Jivanelli, A.R. Bass, Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review. J. Clin. Rheumatol. 28, e498–e505 (2022)
doi: 10.1097/RHU.0000000000001777
pubmed: 34371516
pmcid: 8816970
C. Iadarola, L. Croce, E. Quaquarini, C. Teragni, S. Pinto, A. Bernardo, R. Fonte, M. Marinò, M. Rotondi, L. Chiovato, Nivolumab induced thyroid dysfunction: unusual clinical presentation and challenging diagnosis. Front Endocrinol. (2018). https://doi.org/10.3389/fendo.2018.00813
C.C. Spagnolo, G. Giuffrida, S. Cannavò, T. Franchina, N. Silvestris, R.M. Ruggeri, M. Santarpia, Management of endocrine and metabolic toxicities of immune-checkpoint inhibitors: from clinical studies to a real-life scenario. Cancers (2023). https://doi.org/10.3390/cancers15010246
R.M. Pollack, M. Kagan, M. Lotem, R. Dresner-Pollak, T.S.H. Baseline, level is associated with risk of anti-PD-1-induced thyroid dysfunction. Endocr. Pract. 25, 824–829 (2019)
doi: 10.4158/EP-2018-0472
pubmed: 31013164
D.L. Morganstein, Z. Lai, L. Spain, S. Diem, D. Levine, C. Mace, M. Gore, J. Larkin, Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin. Endocrinol. 86, 614–620 (2017)
doi: 10.1111/cen.13297
M. Ralli, D. Angeletti, M. Fiore, V. D’Aguanno, A. Lambiase, M. Artico, M. de Vincentiis, A. Greco, Hashimoto’s thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev. (2020). https://doi.org/10.1016/j.autrev.2020.102649
Y. Yasuda, S. Iwama, D. Sugiyama, T. Okuji, T. Kobayashi, M. Ito, N. Okada, A. Enomoto, S. Ito, Y. Yan, M. Sugiyama, T. Onoue, Y. Ito, H. Takagi, D. Hagiwara, M. Goto, H. Suga, R. Banno, M. Takahashi, H. Nishikawa, H. Arima, CD4(+) T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci. Transl. Med. (2021). https://doi.org/10.1126/scitranslmed.abb7495
S. Ippolito, G. Di Dalmazi, F. Pani, E. Sabini, P. Caturegli, Distinct cytokine signatures in thyroiditis induced by PD-1 or CTLA-4 blockade: insights from a new mouse model. Thyroid 31, 1839–1849 (2021)
doi: 10.1089/thy.2021.0165
pubmed: 34598661
pmcid: 8721507
R. Gutzmer, A. Koop, F. Meier, J.C. Hassel, P. Terheyden, L. Zimmer, L. Heinzerling, S. Ugurel, C. Pföhler, A. Gesierich, E. Livingstone, I. Satzger, K.C. Kähler, Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur. J. Cancer 75, 24–32 (2017)
doi: 10.1016/j.ejca.2016.12.038
pubmed: 28214654
G.C. Leonardi, J.F. Gainor, M. Altan, S. Kravets, S.E. Dahlberg, L. Gedmintas, R. Azimi, H. Rizvi, J.W. Riess, M.D. Hellmann, M.M. Awad, Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J. Clin. Oncol. 36, 1905–1912 (2018)
doi: 10.1200/JCO.2017.77.0305
pubmed: 29746230
pmcid: 6553840
K.C. Kähler, T.K. Eigentler, A. Gesierich, L. Heinzerling, C. Loquai, F. Meier, F. Meiss, C. Pföhler, M. Schlaak, P. Terheyden, K.M. Thoms, M. Ziemer, L. Zimmer, R. Gutzmer, Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol. Immunother. 67, 825–834 (2018)
doi: 10.1007/s00262-018-2134-z
pubmed: 29487980
S. Hoa, L. Laaouad, J. Roberts, D. Ennis, C. Ye, K. Al Jumaily, J. Pope, T. Nevskaya, A. Saltman, M. Himmel, R. Rottapel, C. Ly, I. Colmegna, A. Fifi-Mah, N. Maltez, A. Tisseverasinghe, M. Hudson, S. Jamal, Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. Cancer Immunol. Immunother. 70, 2197–2207 (2021)
doi: 10.1007/s00262-021-02851-5
pubmed: 33471137
J. Lima Ferreira, C. Costa, B. Marques, S. Castro, M. Victor, J. Oliveira, A.P. Santos, I.L. Sampaio, H. Duarte, A.P. Marques, I. Torres, Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunol. Immunother. 70, 299–309 (2021)
doi: 10.1007/s00262-020-02664-y
pubmed: 32712715
P. Thuillier, C. Joly, Z. Alavi, G. Crouzeix, R. Descourt, G. Quere, V. Kerlan, N. Roudaut, Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study. Cancer Immunol. Immunother. 70, 2023–2033 (2021)
doi: 10.1007/s00262-020-02802-6
pubmed: 33423089
Y.M. Cheung, W. Wang, B. McGregor, O.R. Hamnvik, Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol. Immunother. 71, 1795–1812 (2022)
doi: 10.1007/s00262-021-03128-7
pubmed: 35022907
L. Zhong, Q. Wu, F. Chen, J. Liu, X. Xie, Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunol. Immunother. 70, 2559–2576 (2021)
doi: 10.1007/s00262-020-02803-5
pubmed: 33576872
M. Kfoury, M. Najean, A. Lappara, A.L. Voisin, S. Champiat, J.M. Michot, S. Laghouati, C. Robert, B. Besse, J.C. Soria, O. Lambotte, C. Massard, A. Marabelle, M. Texier, Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. Cancer Treat. Rev. (2022). https://doi.org/10.1016/j.ctrv.2022.102452